Amylyx Pharmaceuticals Inc.

AMLX | NASDAQ

Price Alert Chart Builder DCF Calculator

$32.30

-$0.09 (-0.28%)

Sep 22, 2026, 10:36 AM ET · Market open

Overview Rating Statistics Financials Earnings Analysts Ownership Profile

Market Data

Market Cap $3.6B

Enterprise Value $3.36B

Beta -0.21

Average Volume 2.08M

Shares Outstanding (Diluted) 111.2M

Shares Change YoY 24.75%

Institutional Ownership N/A

Exchange NASDAQ

ISIN US03237H1014

Price Performance

Price Change 1M -16.2%

Price Change 3M 97.9%

Price Change 6M 134.2%

Price Change YTD 183.6%

Price Change 1Y 143.3%

Price Change 3Y 75.3%

Price Change 5Y 79.3%

1M CAGR (ann.) 41.9%

1Y CAGR (ann.) 144.4%

5Y CAGR (ann.) N/A

All-Time CAGR 13.2%

Valuation

PE Ratio -22.97

Forward PE N/A

PEG Ratio -0.39

Forward PEG 1.07

PS Ratio N/A

Forward PS 63.80

PB Ratio 15.06

P/FCF Ratio -28.42

P/Adj. FCF Ratio -23.29

P/OCF Ratio -28.41

EV/Sales N/A

EV/EBIT -22.35

EV/EBITDA -22.40

EV/FCF -26.48

Earnings Yield -4.3%

FCF Yield -3.5%

Adj. FCF Yield -4.3%

Financial Health

Net Cash $250.76M

Total Debt $5.26M

Cash & Short-Term Investments $250.76M

Total Assets $264.56M

Current Ratio 12.12

Quick Ratio 12.12

Debt / Equity Ratio 0.02

Debt / EBITDA -0.04

Debt / FCF -0.04

OCF / Debt -24.09

Interest Coverage 0.00

Altman Z-Score 79.85

Piotroski F-Score 4

Margins & Profitability

Gross Profit Margin 0.0%

Operating Profit Margin 0.0%

EBITDA Margin 0.0%

Net Profit Margin 0.0%

FCF Margin N/A

Adj. FCF Margin N/A

SBC / Revenue 0.0%

SBC Impact (per share) -22.0%

Returns

Return on Assets -57.5%

Return on Equity -52.9%

Return on Invested Capital -66.3%

Return on Capital Employed -66.6%

Return on Tangible Assets -57.5%

Historical Growth (CAGR)

Revenue CAGR 3Y -150.1%

Revenue CAGR 5Y -19.6%

Revenue CAGR 10Y N/A

EPS CAGR 3Y 24.5%

EPS CAGR 5Y 7.2%

EPS CAGR 10Y N/A

FCF CAGR 3Y -28.6%

FCF CAGR 5Y -4.5%

FCF CAGR 10Y N/A

Analyst Forecasts

Analyst Rating Buy

Analyst Count 11

EPS Growth Next 3Y 85.8%

Revenue Growth Next 3Y N/A

Earnings Date Nov 4, 2026

EPS Estimate (next Q) -$0.38

EPS Growth Est (next Q) 2.7%

Revenue Est (next Q) $59.43K

Revenue Growth Est (next Q) N/A

Fair Value Estimates

Graham Number N/A

Graham Upside N/A

Lynch Fair Value N/A

Lynch Upside N/A

Price Target $52.20

Price Target Upside 61.2%

Cash Flow

Operating Cash Flow $-126.58M

Free Cash Flow $-126.72M

Adj. Free Cash Flow $-154.62M

FCF Per Share -$1.14

OCF Per Share -$1.14

OCF/S Ratio 0.0%

Income Statement

Revenue $0

Gross Profit $-20.06M

Operating Income $-162.1M

EBITDA $-149.78M

Net Income $-152.09M

EPS (Diluted) -$1.41

Revenue / Employee N/A

Profit / Employee $-1.12M

Employees 136